240 related articles for article (PubMed ID: 25953645)
21. Matrix metalloproteinases and diabetic vascular complications.
Kadoglou NP; Daskalopoulou SS; Perrea D; Liapis CD
Angiology; 2005; 56(2):173-89. PubMed ID: 15793607
[TBL] [Abstract][Full Text] [Related]
22. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation.
Ferroni P; Basili S; Martini F; Cardarello CM; Ceci F; Di Franco M; Bertazzoni G; Gazzaniga PP; Alessandri C
J Investig Med; 2003 Sep; 51(5):295-300. PubMed ID: 14577520
[TBL] [Abstract][Full Text] [Related]
23. Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus.
Yahagi K; Kolodgie FD; Lutter C; Mori H; Romero ME; Finn AV; Virmani R
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):191-204. PubMed ID: 27908890
[TBL] [Abstract][Full Text] [Related]
24. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits.
Liang J; Liu E; Yu Y; Kitajima S; Koike T; Jin Y; Morimoto M; Hatakeyama K; Asada Y; Watanabe T; Sasaguri Y; Watanabe S; Fan J
Circulation; 2006 Apr; 113(16):1993-2001. PubMed ID: 16636188
[TBL] [Abstract][Full Text] [Related]
25. High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events.
Rattik S; Wigren M; Björkbacka H; Fredrikson GN; Hedblad B; Siegbahn A; Bengtsson E; Schiopu A; Edsfeldt A; Dunér P; Grufman H; Gonçalves I; Nilsson J
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):222-8. PubMed ID: 25359857
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study.
Nambi V; Morrison AC; Hoogeveen RC; Coresh J; Miles S; Rhodes CE; Sharrett AR; Boerwinkle BE; Ballantyne CM
Tex Heart Inst J; 2008; 35(4):388-94. PubMed ID: 19156230
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
28. Matrix Metalloproteinases in COPD and atherosclerosis with emphasis on the effects of smoking.
Kraen M; Frantz S; Nihlén U; Engström G; Löfdahl CG; Wollmer P; Dencker M
PLoS One; 2019; 14(2):e0211987. PubMed ID: 30789935
[TBL] [Abstract][Full Text] [Related]
29. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability.
Zhou YJ; Wang JH; Li L; Yang HW; Wen de L; He QC
Biochem Biophys Res Commun; 2007 Nov; 363(1):30-6. PubMed ID: 17825794
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis.
Abbas A; Aukrust P; Russell D; Krohg-Sørensen K; Almås T; Bundgaard D; Bjerkeli V; Sagen EL; Michelsen AE; Dahl TB; Holm S; Ueland T; Skjelland M; Halvorsen B
PLoS One; 2014; 9(1):e84935. PubMed ID: 24400123
[TBL] [Abstract][Full Text] [Related]
31. Metalloproteinases and advanced glycation end products: coupled navigation in atherosclerotic plaque pathophysiology?
Furfaro AL; Sanguineti R; Storace D; Monacelli F; Puzzo A; Pronzato MA; Odetti P; Traverso N
Exp Clin Endocrinol Diabetes; 2012 Nov; 120(10):586-90. PubMed ID: 23073918
[TBL] [Abstract][Full Text] [Related]
32. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions.
Zaoui P; Cantin JF; Alimardani-Bessette M; Monier F; Halimi S; Morel F; Cordonnier D
Diabetes Metab; 2000 Jul; 26 Suppl 4():25-9. PubMed ID: 10922970
[TBL] [Abstract][Full Text] [Related]
33. The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8.
Kadoglou NP; Sailer N; Fotiadis G; Kapelouzou A; Liapis CD
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):44-9. PubMed ID: 24464597
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-21 is a unique signature associated with coronary plaque instability in humans by regulating matrix metalloproteinase-9 via reversion-inducing cysteine-rich protein with Kazal motifs.
Fan X; Wang E; Wang X; Cong X; Chen X
Exp Mol Pathol; 2014 Apr; 96(2):242-9. PubMed ID: 24594117
[TBL] [Abstract][Full Text] [Related]
35. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events.
Lenti M; Falcinelli E; Pompili M; de Rango P; Conti V; Guglielmini G; Momi S; Corazzi T; Giordano G; Gresele P
Thromb Haemost; 2014 Jun; 111(6):1089-101. PubMed ID: 24499865
[TBL] [Abstract][Full Text] [Related]
37. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.
Luttun A; Lutgens E; Manderveld A; Maris K; Collen D; Carmeliet P; Moons L
Circulation; 2004 Mar; 109(11):1408-14. PubMed ID: 14993123
[TBL] [Abstract][Full Text] [Related]
38. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
[TBL] [Abstract][Full Text] [Related]
39. The role of matrix metalloproteinases in atherothrombosis.
Ketelhuth DF; Bäck M
Curr Atheroscler Rep; 2011 Apr; 13(2):162-9. PubMed ID: 21271310
[TBL] [Abstract][Full Text] [Related]
40. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
